home / stock / ymab / ymab news

YMAB News and Press, Y-mAbs Therapeutics Inc. From 11/17/22

Stock Information
Company Name: Y-mAbs Therapeutics Inc.
Stock Symbol: YMAB
Market: NASDAQ
Website: ymabs.com
Menu
YMAB YMAB Quote YMAB Short YMAB News YMAB Articles YMAB Message Board
Get YMAB Alerts

News, Short Squeeze, Breakout and More Instantly...
YMAB - YMAB INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations

SAN FRANCISCO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now . Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) Investigation: The investigation focuses on Y-...
YMAB - Y-mAbs Therapeutics, Inc. (YMAB) Q3 2022 Earnings Call Transcript

Y-mAbs Therapeutics, Inc. (YMAB) Q3 2022 Earnings Conference Call November 08, 2022, 16:00 ET Company Participants Thomas Gad - Founder, Interim CEO & President Sue Smith - SVP & Chief Commercial Officer Bo Kruse - EVP, Secretary, Treasurer & CFO ...

YMAB - 3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240%

MACK Stock Explodes 240%+ Overnight, Here Are 3 Penny Stocks To Watch Now Thanks to the 2022 stock market crash, there are plenty of penny stocks to watch. The broad market sell-off has taken even some of the most popular names and sent them below the $5 mark. That might be bad for ...

YMAB - YMAB INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Investors in Y-mAbs Therapeutics (YMAB) With Significant Losses to Contact the Firm's Attorneys, Firm Investigating Possible Securities Law Violations

SAN FRANCISCO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/YMAB Contact An Attorney Now: YMAB@hbsslaw....
YMAB - Y-mAbs Therapeutics GAAP EPS of -$0.63 beats by $0.07, revenue of $12.5M beats by $0.49M

Y-mAbs Therapeutics press release ( NASDAQ: YMAB ): Q3 GAAP EPS of -$0.63 beats by $0.07 . Revenue of $12.5M (+39.4% Y/Y) beats by $0.49M . Shares +7.5% . Cash position of $114.5 million as of September 30, 2022, anticipated runway into mid-2024. ...

YMAB - Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Q3 2022 DANYELZA® record product revenues of $12.5 million, YoY growth of 40% and 28% sequential increase compared to Q2 2022 DANYELZA marketing authorization granted in Israel; regulatory filing submitted in Brazil Management reiterates financial guidance, includin...

YMAB - Y-mAbs Therapeutics Investigated by Block & Leviton for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Boston, Massachusetts--(Newsfile Corp. - November 3, 2022) - Block & Leviton is investigating Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) for potential securities law violations. Investors who have lost money in their Y-mAbs Therapeutics, Inc. investment should contact the firm to learn mor...
YMAB - YMAB ALERT: Hagens Berman, National Trial Attorneys, Encourages Investors in Y-mAbs Therapeutics (YMAB) With Significant Losses to Contact the Firm's Attorneys, Firm Investigating Possible Securities Law Violations

SAN FRANCISCO, CA / ACCESSWIRE / November 3, 2022 / - Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/YMAB Contact An Attorney Now: YMAB@hbsslaw.com 844-916...

YMAB - Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022

NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended September 30, 2022, on Monday, November 7, 2022, after the close ...

YMAB - HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Y-mAbs Therapeutics (YMAB) With Significant Losses to Contact the Firm's Attorneys, Firm Investigating Possible Securities Law Violations

SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/YMAB Contact An Attorney Now: YMAB@hbsslaw....
Previous 10 Next 10